Citizens Maintains Market Outperform on Evolent Health, Lowers Price Target to $10
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
Citizens analyst Constantine Davides maintains Evolent Health (NYSE:EVH) with a Market Outperform and lowers the price target from $11 to $10.
Citizens analyst Constantine Davides maintains Evolent Health (NYSE:EVH) with a Market Outperform and lowers the price target from $11 to $10.